Abiomed Recovering Hearts. Saving Lives
Our Company Investors News Products Clinicians Patients & Families

Press Releases
Articles
Archives

Press Contact:
Liza Heapes
Ph: 978-646-1668
Email: lheapes@abiomed.com

 
DANVERS, Mass. (November 13, 2006)-Abiomed, Inc. (NASDAQ: ABMD) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Lazard Capital Markets Third Annual Life Sciences Conference on November 28, 2006 at 9: 00 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.

 

ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the minimally invasive Impella® Circulatory Support System under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.


Contacts:
Daniel Sutherby Liza Heapes
Abiomed, Inc. Abiomed, Inc.
Chief Financial Officer Media Relations
978-646-1812 978-646-1668
ir@abiomed.com mediarelations@abiomed.com


FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

###